Summary & Overview
HCPCS Level II J3305: Trimetrexate Glucuronate Injection, 25 mg
HCPCS Level II code J3305 represents the injectable medication trimetrexate glucuronate, billed per 25 mg unit. As an antineoplastic agent administered parenterally, this code is used in oncology treatment settings and for specialized infusion therapy. Nationally, accurate use of J3305 supports precise drug utilization tracking, billing clarity for chemotherapy regimens, and consistency in coverage determinations across payers.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for trimetrexate glucuronate, common sites of service where the injection is delivered, and the implications for billing workflows. The publication also summarizes benchmarking elements and policy-relevant considerations that affect reimbursement and claims processing for injectable antineoplastic drugs.
The report is designed for revenue cycle managers, clinical billing staff, and policy analysts seeking: clear identification of the HCPCS Level II code and clinical purpose, an outline of typical service locations, and a roadmap of the analytical content readers can expect regarding benchmarks and relevant policy updates. Data not available in the input will be flagged as such in detailed sections.
Billing Code Overview
HCPCS Level II code J3305 describes an injection of trimetrexate glucuronate, billed per 25 mg. This code represents administration of a chemotherapeutic or antineoplastic agent formulated as trimetrexate glucuronate.
-
Service type: Injectable medication administration (antineoplastic/chemotherapy agent)
-
Typical site of service: Hospital outpatient departments, physician offices, ambulatory infusion centers, or other sites where parenteral chemotherapy is administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a history of refractory Pneumocystis jirovecii pneumonia (PJP) who is intolerant to first-line therapies presents to an outpatient infusion center for antimicrobial therapy. The clinician prescribes trimetrexate glucuronate administered by intravenous injection, billed as J3305 per 25 mg unit. The infusion nurse verifies weight-based dosing, reviews allergies and prior adverse reactions to sulfonamides and TMP-SMX, obtains baseline vital signs and renal/hepatic laboratory values, and secures intravenous access. The medication is prepared under sterile conditions by pharmacy, labeled with concentration and lot number, and delivered to the treatment area. During administration, nursing documents start and stop times, total units administered, any premedication provided, and patient tolerance. Post-administration monitoring addresses infusion reactions and vital signs; follow-up includes assessment of clinical response and repeat laboratory monitoring for cytopenias or hepatic toxicity. Typical sites of service include hospital inpatient units, hospital outpatient infusion centers, and specialized ambulatory infusion clinics experienced in handling antimicrobial injections.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when administration required substantially greater resources (e.g., complex dosing adjustments or extended monitoring beyond usual). |